Metastatic malignant neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Metastatic malignant neoplasm
- Therapeutic area
- Oncology
- metastatic malignant neoplasm
- malignant metastatic neoplasm
- metastatic cancer
- metastatic malignant neoplasm
- metastatic neoplasm, malignant
- All therapeutic areas
- Oncology
- Severity
- Terminal
- MONDO ID
- MONDO:0024880
- Parent condition
- MONDO:0024881
Related records
Broader conditions (10)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Metastatic neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Secondary malignant neoplasm
- Secondary neoplasm
Narrower conditions (11)
- Krukenberg carcinoma
- Metastasis from malignant tumor of colon
- Metastatic carcinoma
- Metastatic carcinoma in the adrenal medulla
- Metastatic carcinoma in the bone
- Metastatic malignant neoplasm in the brain
- Metastatic malignant neoplasm in the colon
- Metastatic malignant neoplasm in the eye
- Metastatic malignant neoplasm in the spinal cord
- Metastatic squamous cell carcinoma
- Neoplastic meningitis
Trials (1,131)
- 18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
- 18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
- 18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery
- 18F-FMAU PET/CT in Imaging Patients With Advanced Cancers
- 3D Prediction of Patient-Specific Response
- 68Ga-FAPI PET/CT in Malignant Tumors
- 68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients
- 68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
- 68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
- 68Ga-NI-FAPI PET/CT: First-in-human Study
- 90-Day Mortality After Emergency Department Discharge in Advanced Cancer
- A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
- A Biomarker Screening Protocol for Participants With Solid Tumors
- A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial
- A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
- A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
- A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
- A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
- A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Drugs in development (16)
- APTO-253 Phase 1
- ARRY-382 Phase 1
- Celecoxib Phase 2
- Docetaxel Phase 1
- Dostarlimab Phase 1
- Efaproxiral Phase 3
- Enoblituzumab Phase 1
- LY-2624587 Phase 1
- LY-3007113 Phase 1
- Mitomycin Phase 2
- Pembrolizumab Phase 2
- Pixantrone Phase 1
- Plozalizumab Phase 2
- TALC Phase 3
- Temozolomide Phase 3
- Vadimezan Phase 1
Other linked drugs (7)
- Acetaminophen
- Adagrasib
- Bemcentinib
- Irsogladine
- Oxycodone
- Pyrimidine
- Tempol